Home›Companies›Biotech & Pharma›Eolo Pharma

Eolo Usa, Inc.

Develops potential drugs for people with obesity and metabolic diseases.

Updated Nov 21, 2026·Latest SEC filing Feb 14, 2023·Suggest an edit

About Eolo Pharma

Eolo Pharma is a private company based in Wilmington, Delaware, incorporated in 2019 in Delaware. It has reported $1,799,999 raised in one offering on Form D since February 2023. Its chief executive is Maria Garat.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Sep 7, 2022Feb 8, 2023amended Feb 14, 2023$1,799,999of $2.9M target9$199KEquityRule 506(b)Form D/A ↗1 earlier filing

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Eolo Pharma's Form D filed Feb 14, 2023.

NT
Nicolas Tognalli
Board Member
First appears on the amended Form D that Eolo Pharma filed on February 14, 2023; on 1 of its 2 filings.
CE
Carlos Escande
CSO and Board Member
First appears on the amended Form D that Eolo Pharma filed on February 14, 2023; on 1 of its 2 filings.
PE
Paul Elberse
Board Member
On every Form D that Eolo Pharma has filed: 2 filings, from Feb 8, 2023 to Feb 14, 2023.
MG
Maria Garat
CEO and director
First appears on the amended Form D that Eolo Pharma filed on February 14, 2023; on 1 of its 2 filings.
RH
Roland Haag
Board Member
On every Form D that Eolo Pharma has filed: 2 filings, from Feb 8, 2023 to Feb 14, 2023.

Sources

  1. SECEOLO USA, Inc. Form D, filed Feb 8, 2023
  2. SECEOLO USA, Inc. filing history
  3. CompanyEolo Pharma about and team